1. A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation 
Mark H. Kirschbaum, Anthony S. Stein, Leslie Popplewell, Maria Delioukina, Robert Chen, Ryotaro Nakamura, David Snyder, Joel Conrad, Simon F. Lacey, Paul Frankel, Andrew Dagis, Auayporn Nademanee, Stephen J. Forman 
Biology of Blood and Marrow Transplantation 
Volume 18, Issue 3, Pages (March 2012)
DOI: /j.bbmt
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Treatment schema. Treatments are shown on the timeline spanning the days before stem cell infusion on day 0. Mel, melphalan.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Reconstitution of immune cell subsets. Mean cell numbers are plotted for 15 patients. Error bars indicate standard error. Subsets were defined as follows: CD4 T cells (CD3+, CD45+, CD4+), CD8 T cells (CD3+, CD45+, CD8+), NK cells (CD45+, CD3−, CD16+, CD56+), B cells (CD45+, CD5−, CD19+). Dotted lines represent the upper and lower ranges of normal values.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
OS and EFS estimates for the 12 patients at dose level 2 (clofarabine 40 mg/m2 and melphalan 100 mg/m2), who had a median follow-up time of 16.8 months.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions